logo-loader
Medlab Clinical Ltd

Medlab Clinical obtains positive data proving efficacy of NanaBidial medicinal cannabis in completed phase-one trial

The clinical study was a blinded, randomised trial showing plasma concentrations were achieved quickly with a product half-life of about four hours.

Medlab Clinical Ltd - Medlab Clinical obtains positive data proving efficacy of NanaBidial medicinal cannabis in completed phase-one trial
Medlab’s nano-particle medicine delivery system NanoCelle is being applied to its medicines, nutritional products and off-patent drugs

Medlab Clinical Ltd (ASX:MDC) has obtained crucial pharmacokinetic (PK) study data after completion and independent review of its second PK study using fully completed NanaBidial formulation.

NanaBidial is a high CBD, low THC-containing formula using Medlab’s proprietary delivery platform NanoCelle.

It has proven safe, fast-acting and positive for absorption and metabolism in a healthy human cohort.

Proving the product’s efficacy

Medlab chief executive officer Sean Hall said the company was in a unique and privileged position, possessing proof through clinical studies that its cannabis formulations are absorbed and how the body reacts and metabolises.

He said: “This is essential to regulatory efforts in proving the product’s efficacy and more-so to the medical community who require a detailed understanding of the body’s utilisation of any given pharmaceutical product.

Commercially strong position

Medlab now holds PK data for both the NanaBis and NanaBidial, for various patient cohorts.

While there is some inter-study variability, this was expected considering the candidates used in the various PK programs.

The current result now provides Medlab with a further rounded, holistic view on how the human body will utilise Medlab’s cannabis-based medicine products.

Positive data from the clinical trial also puts Medlab in a commercially strong position.

“Better option than other offerings”

Hall continued: “We are bringing to an effective conclusion the debate as to how NanoCelle cannabis formulations work, how they are absorbed and how they are eliminated, and thus why NanoCelle cannabis formulations are a better option than other offerings.

“The benefit is the uniqueness that these profiles provide for each product, with the knowledge that they cannot be surrogated by other cannabis marketers.

“Medlab is (as so far as the global cannabis market is concerned) one of the very small handful of companies that hold such evidence for their products.”

Quick facts: Medlab Clinical Ltd

Price: $0.48

Market: ASX
Market Cap: $103.38 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Medlab Clinical Ltd named herein, including the promotion by the Company of Medlab Clinical Ltd in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Medlab Clinical forges ahead in new vitamin trials for chronic illnesses

Medlab Clinical Ltd (ASX:MDC) chief executive officer Sean Hall tells Proactive Investors how the company is tapping into new areas of its “therapeutic toolkit” to better assist those with chronic health conditions.   Hall says there has been a shortfall in the standard of...

on 8/5/19

2 min read